García-Cárceles, J., Vázquez-Villa, H., Brea Floriani, J. M., Ladron de Guevara-Miranda, D., Cincilla, G., Sánchez-Martínez, M., . . . López-Rodríguez, M. L. (2022). 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease.
Citación estilo ChicagoGarcía-Cárceles, Javier, et al. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease. 2022.
Cita MLAGarcía-Cárceles, Javier, et al. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease. 2022.